Navigation Links
The Medicines Patent Pool (MPP) Signs a Collaborative Agreement with the University of Liverpool to Develop HIV Nanomedicines
Date:11/30/2015

GENEVA, December 1, 2015 /PRNewswire/ --

Partnership includes an MPP licence for the university's Solid Drug Nanoparticle (SDN) Technology; Aims to support treatment scale-up through cost cuts of priority antiretrovirals (ARVs) 

The Medicines Patent Pool (MPP) today announced a collaboration with the University of Liverpool and a licence for the university's Solid Drug Nanoparticle (SDN) technology to accelerate the development of WHO-recommended antiretrovirals as nanomedicines. The agreement covers a territory of all 135 low- and middle-income countries and two high-income countries in Africa, where licensees based anywhere in the world will have the right to make, use and distribute lower cost ARVs based on SDN technology.

     (Logo: http://photos.prnewswire.com/prnh/20151026/280525LOGO)

"With the World Health Organization's "treat-all" recommendations, more than 20 million people are still in need of viable, sustainable treatment options," said Greg Perry, Executive Director of the MPP. "This partnership seeks to help meet new international HIV scale-up targets through the delivery of better-adapted low-dose medicines at a significant price reduction."

"We are thrilled the MPP has joined us to develop medicines based on SDN technology and to ensure that once developed, they will reach people who need them the most in developing countries," said the University of Liverpool's Vice Chancellor Janet Beer.

The University of Liverpool is one of the UK's leading research institutions with global leadership in the field of HIV and nanotechnology. Their nanotechnology programme aims to overcome some of the challenges of antiretroviral treatment today, including poor solubility and the need to administer large doses to ensure that enough of the drug is absorbed into the body to be effective. With an initial grant from the Research Council UK, University of Liverpool researchers have reformulated two HIV medicines to date and expect to conduct human trials of some of the first oral HIV nanomedicines this month. Currently, there are no HIV nanomedicines on the market.

Professor Andrew Owen from the University's Department of Pharmacology said, "dose reduction can lead to easier administration and potentially fewer side effects for people living with HIV. Smaller oral pills also facilitate lower production costs of active pharmaceutical ingredients which could slash treatment bills and allow health ministries to provide treatment to more people." Professor Steve Rannard from the University's Department of Chemistry added, "the university is proud of its interdisciplinary work in this area, which is a triumph of cross-faculty collaborative research."

Under the terms of the agreement, the University of Liverpool will develop nanoparticles of ARVs licensed to the MPP such as atazanavir, darunavir and lopinavir to improve their solubility and thus reduce dosage. The MPP and the University of Liverpool will engage with pharmaceutical partners for product development and industrial scale-up. The MPP will then sub-license the nano-formulated ARVs and facilitate competitive manufacturing to spur wide distribution of the new medicines in low- and middle-income countries.

"This collaboration marries the best of two leaders in the HIV medicines space - MPP with its tremendous record in licensing priority ARVs for adults and children of all ages and the University of Liverpool with the technology to revolutionise the way these ARVs are delivered," said Philippe Douste-Blazy, Chair of the Executive Board at UNITAID. "We are proud to back the MPP-University of Liverpool initiative."

About the University of Liverpool's Solid Drug Nanoparticle (SDN) Technology Programme  

Nanotechnology involves the reduction of matter to the scale of a billionth of a meter (1/800 of a human hair) and is widely used in fields such as electronics, cosmetics and energy. Nanomedicines have been approved for the treatment of cancers, hepatitis and other disease areas, but the application is relatively new to the area of HIV. The university's SDN technology allows the reformulation of poorly soluble and insoluble drugs into water dispersible formulations and can improve the delivery of drugs into the body.  This improved bioavailability allows reductions in the drug dosage and enables those drugs previously unsuitable for oral delivery to become orally bioavailable with therapeutically relevant pharmacokinetics.

About the Medicines Patent Pool 

The Medicines Patent Pool is a United Nations-back public health organisation working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. Through its innovative business model, the MPP partners with industry, civil society, international organisations, patient groups and other stakeholders to prioritise, forecast and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations. To date, the MPP has signed agreements with six patent holders for twelve HIV antiretrovirals and for one hepatitis C direct-acting antiviral. Its generic partners have distributed more than three billion doses of low-cost medicines to 117 countries. The MPP was founded and remains fully funded by UNITAID.



'/>"/>
SOURCE Medicines Patent Pool
Copyright©2015 PR Newswire.
All rights reserved


Related biology technology :

1. Clearing up inflammation with pro-resolving nanomedicines
2. Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets
3. Freeslate Collaborates with Medicines for Malaria Venture to Advance Therapeutic for Treating Malaria
4. Todays Research: Life Technologies, Opko Health, Medicines, and DaVita
5. Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners
6. H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
7. Fujitsu and ACRES Ally to Enhance Safety and Accelerate Medicines Development
8. Neumedicines Receives Award of $14 Million from BARDA for Continued Development of HemaMax™ as a Medical Countermeasure to Acute Radiation Exposure
9. Local Volunteers Play Valuable Role in Developing New Medicines in Croydon
10. Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd
11. Rx&D responds to PMPRB report: overall impact of medicines must always be considered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... and OXFORD, England , Aug. 16, ... consortium for biotech executive search and leadership development, and Virdis ... sectors, have created an exclusive alliance that enables clients to ... "For our clients here in the ... unparalleled access to a diverse population of leadership talent throughout ...
(Date:8/15/2017)... ... 15, 2017 , ... Any expert in stem cell research or stem cell ... than half a century. Despite their essential roles in human health and regenerative ... molecular tags developed for this purpose also tag other, more abundant, non-stem tissue cells ...
(Date:8/14/2017)... (PRWEB) , ... August 14, 2017 , ... ... characterized and performing antibodies. Key researchers in the antibody community have recently come ... and consistency for antibodies in the laboratory. , The team at ...
(Date:8/11/2017)... ... August 11, 2017 , ... Algenist continues to disrupt the skincare ... like never before. , Collagen is the key structural element skin needs to ... Collagen™, which include: , First to market with proprietary ...
Breaking Biology Technology:
(Date:8/15/2017)... , Aug. 15 2017   ivWatch LLC , a medical ... (IV) therapy, today announced receipt of its ISO 13485 Certification, the ... the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for the early detection ... "This is an important ...
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their boarding ... ... biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at the ... to allow eligible Delta SkyMiles Members who are enrolled in CLEAR to ...
(Date:6/30/2017)... 2017 Today, American Trucking Associations announced ... face and eye tracking software, became the newest ... "Artificial intelligence and advanced sensing ... a driver,s attentiveness levels while on the road.  ... detect fatigue and prevent potential accidents, which could ...
Breaking Biology News(10 mins):